Loading...

NERV MINERVA NEUROSCIENCES INC Capital Structure Changes 8-K Filing

MNRV

NRV

MINERVA NEUROSCIENCES INC

(NERV)

2026 8-K

Board Amendments Approved

Stock Offering Agreement

Financial Results Update

Annual Meeting Notice

Management Change

Financial Results Released

KOL Event Announcement

Stockholder Meeting Outcome

Director Appointment

Funding Agreement Announced

Nasdaq Compliance

Nasdaq Compliance

Annual Meeting Results

Nasdaq Delisting Notice

Annual Meeting Notice

Resignation of Director

FDA Response Letter

Annual Meeting of Stockholders

Private Placement

Compliance Notice from Nasdaq

Resignation of Director

FDA Filing for New Drug App...

External Links:

On May 27, 2026, Minerva Neurosciences, Inc. entered into a Sales Agreement with Leerink Partners LLC to potentially offer up to $75 million in common stock under an 'at-the-market' program. Additionally, the company is revising its Phase 3 trial for roluperidone with results expected in the second half of 2027.

AI Assistant

MINERVA NEUROSCIENCES INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.